Revelation Biosciences, Inc. $(REVB)$, a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, has announced the pricing of a $4 million public offering. The offering includes 3,640,000 shares of common stock, along with warrants to purchase up to 14,560,000 additional shares at an offering price of $1.10 per share and associated warrant. The warrants, exercisable upon stockholder approval, will expire five years after the initial exercise date. Roth Capital Partners is acting as the sole placement agent for the offering. The company plans to use the net proceeds to advance its product development, including ongoing clinical studies, manufacturing, preclinical research, and general corporate purposes.